绝经后骨质疏松的治疗探讨

Study of the treatment for postmenopausal osteoporosis

对经X线骨密度仪检测L2～4的骨密度（BMD）诊断为绝经后骨质疏松（PMO）的86例妇女的血清雌二醇（E2）含量进行RIA测定．其E2含量均值为61．38pmol／L。对本组86例PMO妇女给予小剂量利维爱为主的联合用药治疗6个月．对照观察用药前后BMD、血清钙（Ca）、磷（P）、碱性磷酸酶（ALP）的变化。结果显示．用药后BMD均有不同程度的提高．以绝经时间≤10年者尤为明显（P＜0.01）；绝经时间＞10年者虽有提高．但差异不显著（P＞0.05）。治疗前血清Ca增高30例．占34.88％；P降低29例．占33.72％；ALP增高51例．占59．3％。治疗后均恢复正常。提示联合用药可减少利维爱的用量，是PMO较为理想的治疗方案。绝经后任何时期用药都可防止骨的继续丢失，早期治疗效果更好。

Test a kind treatment for postmenopausal osteoporosis(PMO) of women. We have treated the 86 case of women with PMO with comprehensive treatment mainly with low-dosage of LwiAL for six months,and observed. their BMD increased obviously,specially whose meropausal time were less than 10 years (P< 0. 01),Ca,P.ALP in sera returned to normal. The above treatment is more effective comparely and may reduce the dosage of LIVIAL.